FOXO4-DRI vs SS-31 (2026): Senolytic Clearance vs Mitochondrial Protection Research
FOXO4-DRI vs SS-31: a 2017 Cell mouse study vs 2026 cardiomyocyte data compared. See how senolytic clearance differs from mitochondrial protection in research.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
FOXO4-DRI vs SS-31 is a comparison between two preclinical longevity research peptides that act on different layers of cellular aging: one disrupts a protein-protein interaction to remove senescent cells, the other accumulates at the inner mitochondrial membrane to limit oxidative damage. Researchers studying aging biology often discuss them together because both appear in the anti-aging literature, yet their targets, readouts and evidence bases barely overlap.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Quick Answer: FOXO4-DRI is a senolytic peptide that disrupts the FOXO4-p53 interaction to trigger apoptosis in senescent cells, whereas SS-31 (elamipretide) is a cardiolipin-targeted peptide that reduces mitochondrial hydrogen peroxide burden without killing cells. FOXO4-DRI is purely preclinical; SS-31 has been studied in both preclinical models and early-phase clinical settings.
TL;DR:
- FOXO4-DRI clears senescent cells; SS-31 protects mitochondrial membranes in cells that remain.
- FOXO4-DRI evidence comes from a 2017 Cell study in mouse models (PMID 28340339).
- SS-31 evidence in the library centres on cardiomyocyte models of doxorubicin injury (PMID 42013545).
- No human trials of FOXO4-DRI have been registered; SS-31 has early-phase human data.
- The two act on different targets, so they are best read as complementary hypotheses, not substitutes.
FOXO4-DRI: mechanism and evidence base
FOXO4-DRI is a D-retro-inverso peptide designed by Baar and colleagues at the Hubrecht Institute. Senescent cells resist apoptosis partly because FOXO4 binds nuclear p53 and holds it in a survival-promoting state. The FOXO4-DRI sequence competes for that interaction, which releases p53 to the cytoplasm where it can initiate apoptosis. Because the interaction is most pronounced in senescent cells, the peptide was reported to remove them selectively while sparing non-senescent cells.
The primary study, PMID 28340339, "Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging" (Cell, 2017), reported that in aged mice treatment was associated with restored fur density, improved kidney function and increased exercise tolerance. These are preclinical observations in rodents. The library profile records no registered human trials, and FOXO4-DRI remains a laboratory research compound.
For related senolytic context, see the Epitalon library profile, which represents a different longevity hypothesis centred on telomere biology rather than cell clearance.
SS-31: mechanism and evidence base
SS-31 (Szeto-Schiller peptide 31, INN elamipretide) is a short synthetic tetrapeptide that accumulates in the inner mitochondrial membrane, where it associates with cardiolipin. Cardiolipin is a phospholipid that organises respiratory chain supercomplexes, and its oxidation is a recognised feature of mitochondrial dysfunction. Instead of removing cells, SS-31 is studied for its ability to reduce reactive oxygen species at the membrane and to preserve membrane integrity.
The study attached to the library record, PMID 42013545: "Peroxiredoxin III safeguards cardiac function against doxorubicin by regulating mitochondrial quality control via H2O2 detoxification" (2026), used rat H9c2 cardiomyocytes and mouse models. Cells lacking the mitochondrial antioxidant enzyme peroxiredoxin III showed more than ten-fold hydrogen peroxide accumulation and worse cardiolipin oxidation after doxorubicin exposure, and SS-31 was reported to rescue cardiac dysfunction in the deficient mice by lowering that burden and supporting mitophagy and autophagic flux. This is a mechanistic cardiac-injury model, not an aging study per se, and readers should interpret it accordingly.
Researchers comparing SS-31 with other mitochondrial peptides can also consult the MOTS-c library profile and the existing SS-31 vs MOTS-c comparison.
Side-by-side comparison
| Feature | FOXO4-DRI | SS-31 (elamipretide) |
|---|---|---|
| Primary target | FOXO4-p53 interaction | Cardiolipin, inner mitochondrial membrane |
| Net cellular outcome | Apoptosis of senescent cells | Reduced oxidative damage in surviving cells |
| Key citation | PMID 28340339 (Cell, 2017) | PMID 42013545 (2026) |
| Principal models | Aged and chemotoxicity mouse models | Cardiomyocyte cells, PrxIII-deficient mice |
| Human data | None registered | Early-phase studies reported in the literature |
| Research stage | Preclinical | Preclinical and early clinical |
| Aging-hallmark addressed | Cellular senescence | Mitochondrial dysfunction |
Differential research applications
Investigators select FOXO4-DRI when the question concerns senescent-cell burden, for example how clearing p53-protected cells changes tissue function in aged or chemotoxicity-exposed animals. They select SS-31 when the question concerns mitochondrial quality control, cardiolipin oxidation or hydrogen peroxide handling.
Because the mechanisms are distinct, some experimental designs treat them as separate arms probing different aging hallmarks rather than competing interventions. Half-life and pharmacokinetic planning for such designs can start from the half-life chart, and published evidence can be browsed with the evidence explorer.
Experimental readouts and evidence limitations
The two compounds are assessed with very different endpoints. Senolytic studies of FOXO4-DRI typically quantify senescence markers such as p16 and SA-beta-galactosidase positivity, the proportion of cells undergoing p53-dependent apoptosis, and organ-level functional measures in aged animals. In the Cell study (PMID 28340339), tissue-level outcomes were reported alongside the cellular findings, which is why the paper is widely cited as foundational for peptide-based senolytic research.
Mitochondrial peptide studies of SS-31 instead rely on membrane potential, hydrogen peroxide quantification, cardiolipin oxidation, mitophagy flux and fusion protein expression. In the cardiomyocyte work (PMID 42013545), the key contrast was between cells and mice with severe versus moderate mitochondrial hydrogen peroxide accumulation, which let investigators separate the contribution of oxidative burden from other doxorubicin effects.
Several limitations apply to both bodies of evidence. Rodent and cell models do not establish effects in humans, and tissue-specific results may not generalise. FOXO4-DRI data come from a small number of laboratories and, as of 2026, lack independent human replication. The SS-31 study linked to the library record is a cardiotoxicity model, so it informs mitochondrial mechanism more than longevity outcomes. Dose, route and exposure duration differ between studies, so cross-study numerical comparisons are not appropriate. Researchers evaluating either compound should therefore weigh mechanism-level support more heavily than any single functional outcome, and should consult the full library profiles before designing experiments.
Choosing between mechanisms in study design
A practical framing is to match the compound to the hallmark under study. If the hypothesis is that accumulated senescent cells drive tissue decline, FOXO4-DRI offers a tool that removes them through a defined molecular interaction. If the hypothesis is that membrane-level oxidative damage drives functional decline, SS-31 offers a tool that acts on cardiolipin without altering cell number. Studies that need to distinguish the two effects can include separate treatment arms with senescence and mitochondrial readouts measured in parallel, which keeps each mechanism interpretable.
Regulatory and research status
Neither compound should be treated as a general-use product. FOXO4-DRI is listed in the library as not approved, with a 503A compounding status of under review. SS-31 has a more complex regulatory history tied to specific rare-disease indications under investigation; readers should confirm current status on the library profile and directly with FDA sources, since regulatory records change.
Cited studies
- PMID 28340339, "Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging" (Cell, 2017). https://doi.org/10.1016/j.cell.2017.02.031
- PMID 42013545: "Peroxiredoxin III safeguards cardiac function against doxorubicin by regulating mitochondrial quality control via H2O2 detoxification" (2026). https://doi.org/10.1089/ars.2012.4849
Frequently asked questions
Q: What is the difference between FOXO4-DRI and SS-31?
A: FOXO4-DRI is a senolytic peptide that disrupts the FOXO4-p53 interaction so senescent cells undergo apoptosis. SS-31 targets cardiolipin at the inner mitochondrial membrane and is studied for reducing oxidative damage rather than removing cells.
Q: Is FOXO4-DRI a senolytic?
A: Yes. The 2017 Cell study (PMID 28340339) described it as selectively inducing apoptosis in senescent cells in mouse models. It remains a preclinical research compound.
Q: What does SS-31 do in mitochondria?
A: SS-31 accumulates at the inner mitochondrial membrane and associates with cardiolipin. In the cited cardiomyocyte work (PMID 42013545) it reduced hydrogen peroxide burden and supported mitochondrial quality control pathways.
Q: Has either peptide been tested in humans?
A: No human trials of FOXO4-DRI are registered according to the library profile. SS-31 has been examined in early-phase human studies reported in the literature, but its evidence base should be reviewed on its own profile.
Q: Are FOXO4-DRI and SS-31 studied together?
A: They are usually studied separately because they address different aging hallmarks, senescence and mitochondrial dysfunction. Combined designs are conceptually discussed but are not established in the cited literature.
See also:
- FOXO4-DRI vs Epitalon: the other FOXO4-DRI head-to-head, contrasting senolytic and telomere approaches
- SS-31 vs MOTS-c: SS-31 against a mitochondria-derived signalling peptide
- Epitalon, Pinealon and Cortagen: the bioregulator peptide family overview
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.